STRATA Skin Sciences

Regulatory Hurdles And Device Risks Will Constrain Operations Yet Stabilize

AnalystLowTarget

Not Invested

Community Contributor

Published

20 Aug 25

n/a

AnalystLowTarget's Fair Value

n/a

-51.0%

-6.2%

-51.0%

-6.2%

You can edit this narrative until Aug 20 10:10 PM. Then, changes will post as Updates.

Author's Valuation

US$462.0% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$4

62.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

6.53%

Medical Equipment revenue growth rate

0.43%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

11.62%

Calculation

US$4.65m

Earnings '28

4.65x

PE Ratio '28

US$21.64m

Market Cap '28

US$21.64m

Market Cap '28

4.17m

No. shares '28

US$5.19

Share Price '28

US$5.19 Share Price '28

Discounted to 2025 @ 10.58% p.a.

US$3.84

Fair Value '25